The FDA will remove its decades-old black box warning from estrogen-based hormone therapies, citing new evidence that early use after menopause can offer long-term health benefits. The move marks a major reversal of past guidance.
Read Full
Your email address will not be published. Required fields are marked *
Save my name, email, and website in this browser for the next time I comment.
